Biblio

Godfrey L, Iannitelli A, Garrett NLaura, Moger J, Imbert I, King T, Porreca F, Soundararajan R, Lalatsa A, Schätzlein AG et al..  2017.  Nanoparticulate peptide delivery exclusively to the brain produces tolerance free, analgesia.. Journal of Controlled Release. E-pub ahead of print

Fisusi FA, Siew A, Chooi KWai, Okubanjo O, Garrett N, Lalatsa K, Serrano D, Summers I, Moger J, Stapleton P et al..  2016.  Lomustine Nanoparticles Enable Both Bone Marrow Sparing and High Brain Drug Levels - A Strategy for Brain Cancer Treatments.. Pharmaceutical Research. :1-15.

Serrano DR, Lalatsa A, M Dea-Ayuela A, Bilbao-Ramos PE, Garrett NL, Moger J, Guarro J, Capilla J, M Ballesteros P, Schätzlein AG et al..  2015.  Oral particle uptake and organ targeting drives the activity of amphotericin B nanoparticles.. Molecular pharmaceutics. 12(2):420-431.

Chooi KW, Carlos MIsabel Sim, Soundararajan R, Gaisford S, Arifin N, Schätzlein AG, Uchegbu IF.  2014.  Physical Characterisation and Long‐Term Stability Studies on Quaternary Ammonium Palmitoyl Glycol Chitosan (GCPQ)—A New Drug Delivery Polymer. Journal of Pharmaceutical Sciences.

Lalatsa A, Schätzlein AG, Uchegbu IF.  2014.  Strategies To Deliver Peptide Drugs to the Brain. Molecular pharmaceutics. 11(4):1081-1093.

Mazza M, Notman R, Anwar J, Rodger A, Hicks M, Parkinson G, McCarthy D, Daviter T, Moger J, Garrett N et al..  2013.  Nanofiber-based delivery of therapeutic peptides to the brain. ACS nano. 7(2):1016-1026.

Le HThi Bich, Schätzlein AG, Uchegbu IF.  2013.  Polymer Hydrophobicity Has a Positive Effect on the Oral Absorption of Cyclosporine A from Poly(ethylenimine) Based Nanomedicines. Pharmaceutical Nanotechnology. 1:15-25.

Lalatsa A, Lee V, Malkinson JP, Zloh M, Schätzlein AG, Uchegbu IF.  2012.  A Prodrug Nanoparticle Approach for the Oral Delivery of a Hydrophilic Peptide, Leucine 5-enkephalin, to the Brain. Molecular pharmaceutics. 9(6):1665-1680.

Ahmad S, Johnston BF, Mackay SP, Schätzlein AG, Gellert P, Sengupta D, Uchegbu IF.  2010.  In silico modelling of drug-polymer interactions for pharmaceutical formulations.. Journal of The Royal Society Interface. 7 Suppl 4:S423-33.